Multivariate Cox Proportional Hazard Regression Analysis on Factors Affecting the Overall Survival.

<p>*treated as time-dependent variables.</p><p>Multivariate Cox Proportional Hazard Regression Analysis on Factors Affecting the Overall Survival.</p

Raw Incidence of Primary Responsive vs Primary Refractory Disease, According to Main Clinical and Therapeutic Factors, Among 3,106 Patients Evaluable for Response to First Line Therapy.

<p>Raw Incidence of Primary Responsive vs Primary Refractory Disease, According to Main Clinical and Therapeutic Factors, Among 3,106 Patients Evaluable for Response to First Line Therapy.</p

Characteristics of the Study Cohort.

1<p>Among 3,315 assessable patients in our data base, 209 died early, due to early toxic death (n = 163, 4.9%), other cancers (n = 8, 0.2%), unknown reasons (n = 17), probable but not formally proven lymphoma progression (n = 21); overall, 3,106 could be properly evaluated for response to therapy;²B-cell lymphoma was classified into four groups, i.e.: Diffuse Large B-Cell Lymphoma (DLB-CL), Follicular Lymphoma (FL), Mantle-Cell Lymphoma (MCL), and miscellaneous histologies, including marginal-zone (MZL), small lymphocytic (SL), and Burkitt’s and lymphoblastic lymphoma; ³low-grade lymphoma included FL-MZL-SL-low-grade T-cell lymphoma, all remaining subtypes, i.e. MCL, DLCL, transformed-FL, high-grade peripheral T-cell NHL, other aggressive histotypes (Burkitt’s and Burkitt-like NHL, Lymphoblastic lymphoma) were included among intermediate/high-grade histologies; ⁴IPI: International Prognostic Index: assessed in all diffuse large-cell lymphoma, and low-grade lymphoma; ⁵the Lymphocyte to Monocyte (LM) ratio was assessed at diagnosis by automatic blood count; ⁶Chemotherapy was delivered to all patients, according to various schedules, as detailed in the text.</p><p>missing values: * = 1; ** = 73 (2.2%); *** = 526 (15.9%); ^† = 491 (14.8%); ^†† (including cases where IPI was NA) = 818 (24.7%); ^‡ = 1,155 (34.8%); ^††† = 49 (1.5%); ^§ = 66 (2.1%).</p><p>Characteristics of the Study Cohort.</p

Overall Survival in Non-Hodgkin’s Lymphoma (NHL) Patients according to response to primary therapy.

<p><u>A</u>. Overall survival (OS) of 3,106 NHL patients diagnosed and managed during the period 1982–2012. The OS projections are of 82.8%, 69.5%, and 59.2%, for responsive patients, 31.5%, 21.6%, and 15.7% for early progression, 18.9%, 15.2%, and 14.2% for fully refractory patients, at 5, 10, and 15 years, respectively (responsive vs. refractory: p<0.001). Median follow-up for the whole series is 7.5 yrs (range, 0.6–31.2). <u>B</u>. OS of 1,231 NHL patients diagnosed and managed up to 1,999. The OS projections are of 81.4%, 68.1%, and 57.6%, for responsive patients, 26.7%, 17.7%, and 12.4% for early progression, 17.6%, 14.8%, and 13.8% for fully refractory patients, at 5, 10, and 15 years, respectively (responsive vs. refractory: p<0.001). Median follow-up for the whole series is 16 yrs (range, 0.6–31.2) <u>C</u>. OS of 1,875 NHL patients diagnosed and managed since 2,000. The OS projections are of 83.8% and 70.7%, for responsive patients, 39.1% and 28.4%, for early progression, 20.4% and 14.9%, for fully refractory patients, at 5 and 10 years, respectively (responsive vs. refractory: p<0.001). Median follow-up for the whole series is 5.1 yrs (range, 0.6–13.7).</p

Overall Survival of 3,315 Non-Hodgkin’s Lymphoma (NHL) Patients following first line therapy.

<p>At a median follow-up of 7.3 years., the median survival for the entire cohort was of 12.7 yrs. (range: 0–32.6yrs).</p

Raw Incidence of Primary Responsive vs Primary Refractory Patients Among Main B-Cell Lymphoma Subtypes, According to Rituximab Administration.

<p>Blue = responsive, red = fully refractory, brown = early progression, grey = early death. No Rituximab = Chemotherapy without Rituximab; Rituximab = chemotherapy supplemented with Rituximab. DLB-CL: Diffuse Large B-Cell Lymphoma; FL: Follicular Lymphoma; MCL: Mantle-Cell Lymphoma; Miscellaneous B-cell NHL: marginal-zone, small lymphocytic, Burkitt’s and lymphoblastic lymphoma. Data on Rituximab administration were lacking on 21 out of 2,858 B-cell lymphoma patients. <i>p values</i> were calculated for responsive/refractory ratio in No Rituximab compared to Rituximab.</p

Multivariate Binary Logistic Regression Analyses on Factors Associated with Refractory Disease.

<p>Multivariate Binary Logistic Regression Analyses on Factors Associated with Refractory Disease.</p